Completed | June 2022

HIV Drug Resistance Profile in Patients Experiencing Treatment Failure after Transition to a Dolutegravir Based Treatment Regimen in EGPAF Program in Mozambique

Overview

Country:

Mozambique

Subject Matter:

Adult Testing, Care, and Treatment

Data Collection Period: 07/2021 – 02/2022

The purpose of this CDC-funded surveillance study is to describe the HIV drug resistance mutation profile in patients with treatment failure ≥ 6 months after switching to a Dolutegravir-based regimen from another first-line ART regimen in Gaza, Mozambique.

Publications and Presentations:

  1. Findings presented at the 11th International AIDS Society Conference, July 2021: “Pediatric ARV optimization in a real-world setting: Dolutegravir transition in Mozambique“

Explore Other Research

In Analysis Assessing the Effectiveness of Integration of Rapid Antigen Testing for SARS-CoV-2 in MNCH, HIV and TB Services in Cameroon and Kenya: A Pre- and Post- Implementation Evaluation (Effectiveness Integration) Adult Testing, Care, and Treatment; COVID-19; Pediatric and Adolescent Testing, Care, and Treatment
In Analysis Evaluation of the Differentiated Care Model for Advanced HIV Disease in Côte d’Ivoire DICACI study Adult Testing, Care, and Treatment; Pediatric and Adolescent Testing, Care, and Treatment
In Analysis Evaluation of a National Program for Management of Advanced HIV Disease in Lesotho Adult Testing, Care, and Treatment; Pediatric and Adolescent Testing, Care, and Treatment
All Research